

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Afterpay Touch Group Limited	APT.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Manager in the August 2018 placement of Afterpay Touch Group Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Antisense Therapeutics Limited	ANP.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the November 2020 placement bookbuild of Antisense Therapeutics Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Aroa Biosurgery Limited	ARX.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the June 2020 initial public offering of Aroa Biosurgery limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Cleanspace Holdings Limited	CSX.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the September 2020 initial public offering of Cleanspace Holdings Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Collins Foods Limited	CKF.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter to the March 2017 Placement and Joint Lead Manager and Underwriter in the July 2017 Accelerated Non-Renounceable Entitlement Offer of Collins Foods Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
ELMO Software Limited	ELO.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager to the March 2018 Placement of ELMO Software Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter to the June 2017 IPO of ELMO Software Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
EML Payments Limited	EML.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Manager in the November 2019 placement EML Payments Ltd securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
ImpediMed Limited	IPD.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the July 2019 and April 2020 Entitlement Offer of ImpediMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report. Wilsons restricts research analysts from trading in securities for which they write research. Other Wilsons employees may hold interests in the company, but none of those interests are material. Wilsons further advises that at the date of this report, neither Wilsons Advisory and Stockbroking Limited or Wilsons Corporate Finance Limited have any material interests in the company.</p>
Lumos Diagnostics	LDX.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the July 2021 IPO of Lumos Diagnostics Holdings Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Marley Spoon AG	MMM.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Manager in the October 2020 placement of Marley Spoon AG securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Noni B Limited/Mosaic Brands	MOZ.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter in the May 2018 placement and entitlement offer of Noni B Limited securities and Financial Advisor on the November 2019 acquisition of EziBuy Limited for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Nuchev Limited	NUC.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Sole Lead Manager and Underwriter in the December 2019 IPO and the Lead Manager and Underwriter in the July 2020 capital raising of Nuchev Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Oncosil Medical Ltd	OSL.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the April 2018 placement and Share Purchase Plan of Oncosil Medical Ltd securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Pacific Smiles Group Limited	PSQ.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the March 2021 placement of Pacific Smiles Group Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Plenti Group Limited	PLT.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the August 2020 initial public offering of Plenti Group Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Pinnacle Investment Management Group Limited	PNI.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Underwriter in the March 2021 Dividend Reinvestment Plan for Pinnacle Investment Management Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the July 2018 placement of Pinnacle Investment Management Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
ReadyTech Holdings Limited	RDY.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the April 2019 IPO and Lead Manager and Underwriter in the November 2020 Placement of ReadyTech Holdings Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Rural Funds Group	RFF.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager for the July 2021 Equity raising of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager for the July 2018 Entitlement Offer of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Co-Lead Manager and Underwriter in the June 2017 Entitlement Offer of Rural Funds Group securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
SILK Laser Australia Limited	SLA.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the June 2021 Institutional placement of SILK Laser Australia Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the November 2020 initial public offering of SILK Laser Australia Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
SomnoMed Limited	SOM.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager and Underwriter in the March 2020 accelerated pro-rata non-renounceable entitlement offer of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the February 2018 accelerated pro-rata non-renounceable entitlement offer of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited acted as Lead Manager and Underwriter in the May 2016 placement of SomnoMed Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Telix Pharmaceuticals Limited	TLX.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Joint Underwriter to the Telix Pharmaceuticals Limited November 2017 IPO for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>

WILSONS
RESEARCH
COMPANY DISCLOSURES

Company name	Stock Code	Regulatory Disclosure
Top Shelf International Holdings Limited	TSI.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and underwriter in the November 2020 IPO of Top Shelf International Holdings Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
Whispir Limited	WSP.ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the March 2021 Institutional placement and Share Purchase Plan of Whispir Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager in the September 2020 secondary sell down of Whispir Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Joint Lead Manager and Underwriter in the June 2019 IPO of Whispir Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>
5G Networks Limited	5GN:ASX	<p>Wilsons Corporate Finance Limited ACN 057 547 323, AFSL 238 383 acted as Lead Manager in the June 2020 placement, and Lead Manager in the September 2020 placement and secondary sell down for 5G Networks Limited securities for which it received fees or will receive fees for acting in this capacity. Wilsons Advisory and Stockbroking Limited may have a conflict of interest which investors should consider before making an investment decision. Wilsons Advisory and Stockbroking Limited, Wilsons Corporate Finance Limited and its related bodies corporate trades or may trade as principal in the securities that are subject of the research report.</p>